| 1 |
English BA, Ereshefsky L. Experimental Medicine Approaches in Early-Phase CNS Drug Development. Adv Neurobiol 2023;30:417-55. [PMID: 36928860 DOI: 10.1007/978-3-031-21054-9_17] [Reference Citation Analysis]
|
| 2 |
Juza R, Musilek K, Mezeiova E, Soukup O, Korabecny J. Recent advances in dopamine D(2) receptor ligands in the treatment of neuropsychiatric disorders. Med Res Rev 2023;43:55-211. [PMID: 36111795 DOI: 10.1002/med.21923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Kayir H, Ruffolo J, McCunn P, Khokhar JY. The Relationship Between Cannabis, Cognition, and Schizophrenia: It's Complicated. Curr Top Behav Neurosci 2023;63:437-61. [PMID: 36318403 DOI: 10.1007/7854_2022_396] [Reference Citation Analysis]
|
| 4 |
Dean B, Scarr E. Common changes in rat cortical gene expression after chronic treatment with chlorpromazine and haloperidol may be related to their antipsychotic efficacy. Neuroscience Applied 2022. [DOI: 10.1016/j.nsa.2022.101015] [Reference Citation Analysis]
|
| 5 |
Cervenka S, Frick A, Bodén R, Lubberink M. Application of positron emission tomography in psychiatry-methodological developments and future directions. Transl Psychiatry 2022;12:248. [PMID: 35701411 DOI: 10.1038/s41398-022-01990-2] [Reference Citation Analysis]
|
| 6 |
Perlstein I, Merenlender Wagner A, Gomeni R, Lamson M, Harary E, Spiegelstein O, Kalmanczhelyi A, Tiver R, Loupe P, Levi M, Elgart A. Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone. Clin Pharmacol Drug Dev 2022. [PMID: 35245409 DOI: 10.1002/cpdd.1078] [Reference Citation Analysis]
|
| 7 |
Juza R, Vojtechova I, Stefkova-mazochova K, Dehaen W, Petrasek T, Prchal L, Kobrlova T, Janousek J, Vlcek P, Mezeiova E, Svozil D, Karasova JZ, Pejchal J, Stark H, Satala G, Bojarski AJ, Kubacka M, Mogilski S, Randakova A, Musilek K, Soukup O, Korabecny J. Novel D2/5-HT receptor modulators related to cariprazine with potential implication to schizophrenia treatment. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Caligiuri MP, Weiden PJ, Legedza A, Yagoda S, Claxton A. Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study. Schizophrenia Bulletin Open 2022;3. [DOI: 10.1093/schizbullopen/sgac018] [Reference Citation Analysis]
|
| 9 |
Tong E, Yamin G. Introduction to Molecular Neuroimaging Applications. Hybrid PET/MR Neuroimaging 2022. [DOI: 10.1007/978-3-030-82367-2_6] [Reference Citation Analysis]
|
| 10 |
Weston-Green K. Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives. Front Psychiatry 2022;13:903156. [PMID: 35782443 DOI: 10.3389/fpsyt.2022.903156] [Reference Citation Analysis]
|
| 11 |
Schönknecht P. Cariprazine in the Treatment of Psychosis. NeuroPsychopharmacotherapy 2022. [DOI: 10.1007/978-3-030-62059-2_118] [Reference Citation Analysis]
|
| 12 |
Schönknecht P. Cariprazine in the Treatment of Psychosis. NeuroPsychopharmacotherapy 2022. [DOI: 10.1007/978-3-319-56015-1_118-1] [Reference Citation Analysis]
|
| 13 |
Kim JJ, Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Clin Psychopharmacol Neurosci 2021;19:600-9. [PMID: 34690115 DOI: 10.9758/cpn.2021.19.4.600] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 14 |
Ferraiolo M, Atik H, Ponthot R, Belo do Nascimento I, Beckers P, Stove C, Hermans E. Receptor density influences ligand-induced dopamine D2L receptor homodimerization. Eur J Pharmacol 2021;911:174557. [PMID: 34626593 DOI: 10.1016/j.ejphar.2021.174557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Maini K, Hollier JW, Gould H, Bollich V, John LaForge J, Cornett EM, Edinoff AN, Kaye AM, Kaye AD. Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. Health Psychol Res 2021;9:24932. [PMID: 34746489 DOI: 10.52965/001c.24932] [Reference Citation Analysis]
|
| 16 |
Lee M, Fatouros-Bergman H, Plavén-Sigray P, Ikonen Victorsson P, Sellgren CM, Erhardt S, Flyckt L, Farde L, Cervenka S. No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis. NPJ Schizophr 2021;7:46. [PMID: 34548499 DOI: 10.1038/s41537-021-00176-x] [Reference Citation Analysis]
|
| 17 |
Juza R, Stefkova K, Dehaen W, Randakova A, Petrasek T, Vojtechova I, Kobrlova T, Pulkrabkova L, Muckova L, Mecava M, Prchal L, Mezeiova E, Musilek K, Soukup O, Korabecny J. Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D2 3,4-dihydroquinolin-2(1H)-one Derivatives Related to Aripiprazole. Biomolecules 2021;11:1262. [PMID: 34572475 DOI: 10.3390/biom11091262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
A REVIEW OF PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations 2021. [DOI: 10.1002/9781119497813.ch1] [Reference Citation Analysis]
|
| 19 |
Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatr 2021; 11(7): 277-296 [PMID: 34327122 DOI: 10.5498/wjp.v11.i7.277] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 20 |
Seeman MV. History of the dopamine hypothesis of antipsychotic action. World J Psychiatr 2021; 11(7): 355-364 [PMID: 34327128 DOI: 10.5498/wjp.v11.i7.355] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 21 |
Kraguljac NV, McDonald WM, Widge AS, Rodriguez CI, Tohen M, Nemeroff CB. Neuroimaging Biomarkers in Schizophrenia. Am J Psychiatry 2021;178:509-21. [PMID: 33397140 DOI: 10.1176/appi.ajp.2020.20030340] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 22 |
Smart K, Naganawa M, Baldassarri SR, Nabulsi N, Ropchan J, Najafzadeh S, Gao H, Navarro A, Barth V, Esterlis I, Cosgrove KP, Huang Y, Carson RE, Hillmer AT. PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. Cereb Cortex 2021;31:2787-98. [PMID: 33442731 DOI: 10.1093/cercor/bhaa387] [Reference Citation Analysis]
|
| 23 |
Solomon SD, Powell V, Sanches M, Borlido C, Burton L, De Luca V, Rajji T, Remington G. Reliability of the Clozapine:N-Desmethylclozapine (CLZ:NDMC) Ratio. Schizophrenia Bulletin Open 2021;2. [DOI: 10.1093/schizbullopen/sgab048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 24 |
Seeman MV. The Pharmacodynamics of Antipsychotic Drugs in Women and Men. Front Psychiatry 2021;12:650904. [PMID: 33897500 DOI: 10.3389/fpsyt.2021.650904] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 25 |
Ntephe CU, Demjaha A. Dopamine and Response to Antipsychotic Medication. PET and SPECT in Psychiatry 2021. [DOI: 10.1007/978-3-030-57231-0_14] [Reference Citation Analysis]
|
| 26 |
Wong DF, Raoufinia A, Bricmont P, Brašić JR, McQuade RD, Forbes RA, Kikuchi T, Kuwabara H. An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol 2021;77:717-25. [PMID: 33196868 DOI: 10.1007/s00228-020-03021-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 27 |
Nishibe H, Tateno A, Sakayori T, Yamamoto M, Kim W, Kakuyama H, Okubo Y. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia. Int J Neuropsychopharmacol 2021;24:108-17. [PMID: 32936897 DOI: 10.1093/ijnp/pyaa071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
Siwek M, Krupa AJ, Wasik A. Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk. Pharmacotherapy in Psychiatry and Neurology 2020;36:117-134. [DOI: 10.33450/10.33450/fpn.2020.06.002] [Reference Citation Analysis]
|
| 29 |
Zou H, Banerjee P, Leung SSY, Yan X. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Front Pharmacol 2020;11:997. [PMID: 32719604 DOI: 10.3389/fphar.2020.00997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 30 |
Freiburghaus T, Svensson JE, Matheson GJ, Plavén-sigray P, Lundberg J, Farde L, Cervenka S. Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: a PET study of within-subject correlations with [11C]FLB 457.. [DOI: 10.1101/2020.06.01.127027] [Reference Citation Analysis]
|
| 31 |
Arakawa R, Takano A, Halldin C. PET technology for drug development in psychiatry. Neuropsychopharmacol Rep 2020;40:114-21. [PMID: 32463584 DOI: 10.1002/npr2.12084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 32 |
Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D(2) and D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology 2020;45:786-92. [PMID: 31847007 DOI: 10.1038/s41386-019-0590-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 33 |
Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol 2020;10:2045125320937575. [PMID: 32922732 DOI: 10.1177/2045125320937575] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 34 |
Cervenka S, Farde L. Molecular Imaging. Neuroimaging in Schizophrenia 2020. [DOI: 10.1007/978-3-030-35206-6_8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 35 |
Quednow BB, Geyer MA, Halberstadt AL. Serotonin and schizophrenia. Handbook of Behavioral Neuroscience 2020. [DOI: 10.1016/b978-0-444-64125-0.00039-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 36 |
McQueen G, Lay A, Lally J, Gabay AS, Collier T, Lythgoe DJ, Barker GJ, Stone JM, McGuire P, MacCabe JH, Egerton A. Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. Psychopharmacology (Berl) 2020;237:443-51. [PMID: 31786651 DOI: 10.1007/s00213-019-05382-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 37 |
Guarnieri RV, Alves MV, Nogueira AML, de Souza Silva Tudesco I, Galduróz JCF, Covolan L, Bueno OFA. Haloperidol-induced impairment on working memory capacity affecting long term memory performance: the binding hypothesis.. [DOI: 10.1101/2019.12.24.888073] [Reference Citation Analysis]
|
| 38 |
Noel C. A review of a recently published guidelines' "strong recommendation" for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine. Ment Health Clin 2019;9:287-93. [PMID: 31293849 DOI: 10.9740/mhc.2019.07.287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 39 |
Stern S, Linker S, Vadodaria KC, Marchetto MC, Gage FH. Prediction of Response to Drug Therapy in Psychiatric Disorders. FOC 2019;17:294-307. [DOI: 10.1176/appi.focus.17304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 40 |
Manvich DF, Petko AK, Branco RC, Foster SL, Porter-Stransky KA, Stout KA, Newman AH, Miller GW, Paladini CA, Weinshenker D. Selective D(2) and D(3) receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens. Neuropsychopharmacology 2019;44:1445-55. [PMID: 30879021 DOI: 10.1038/s41386-019-0371-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 41 |
Stern S, Linker S, Vadodaria KC, Marchetto MC, Gage FH. Prediction of response to drug therapy in psychiatric disorders. Open Biol. 2018;8. [PMID: 29794033 DOI: 10.1098/rsob.180031] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 42 |
Vanover KE, Davis RE, Zhou Y, Ye W, Brašić JR, Gapasin L, Saillard J, Weingart M, Litman RE, Mates S, Wong DF. Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology 2019;44:598-605. [PMID: 30449883 DOI: 10.1038/s41386-018-0251-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 196] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 43 |
Fountoulakis KN, Nimatoudis I, Stahl SM. Biological Psychiatry and Psychopharmacology. Psychobiology of Behaviour 2019. [DOI: 10.1007/978-3-030-18323-3_13] [Reference Citation Analysis]
|
| 44 |
Suzuki K, Harada A, Suzuki H, Capuani C, Ugolini A, Corsi M, Kimura H. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents. Pharmacol Res Perspect 2018;6. [PMID: 29417763 DOI: 10.1002/prp2.372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 45 |
Manvich DF, Petko AK, Branco RC, Foster SL, Porter-stransky KA, Stout KA, Newman AH, Miller GW, Paladini CA, Weinshenker D. Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens.. [DOI: 10.1101/439398] [Reference Citation Analysis]
|
| 46 |
Burk JA, Blumenthal SA, Maness EB. Neuropharmacology of attention. Eur J Pharmacol 2018;835:162-8. [PMID: 30092180 DOI: 10.1016/j.ejphar.2018.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 47 |
Matheson GJ, Plavén-sigray P, Louzolo A, Borg J, Farde L, Petrovic P, Cervenka S. Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness.. [DOI: 10.1101/321646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 48 |
Kim ES, David Leonardo E, Dranovsky A. iPSC-derived neurons as a tool for probing molecular pharmacology of antipsychotic action.. [DOI: 10.1101/308486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 49 |
Huang C, Wang Z, Liu L, Liu X, Dong J, Xu Q, Zhang B, Miao L. Predicting the dopamine D2 receptor occupancy of ropinirole in rats using positron emission tomography and pharmacokinetic-pharmacodynamic modeling. Xenobiotica 2019;49:143-51. [PMID: 29334326 DOI: 10.1080/00498254.2018.1428383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 50 |
Tateno A, Sakayori T, Kim WC, Honjo K, Nakayama H, Arakawa R, Okubo Y. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. Int J Neuropsychopharmacol 2018;21:522-7. [PMID: 29346639 DOI: 10.1093/ijnp/pyy004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 51 |
Suzuki K, Kimura H. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. CNS Neurosci Ther 2018;24:604-14. [PMID: 29318783 DOI: 10.1111/cns.12798] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 52 |
Behzadan V, Munir A, Yampolskiy RV. A Psychopathological Approach to Safety Engineering in AI and AGI. Developments in Language Theory 2018. [DOI: 10.1007/978-3-319-99229-7_46] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 53 |
Jeon SW, Kim YK. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. Int J Mol Sci 2017;18:E2174. [PMID: 29057817 DOI: 10.3390/ijms18102174] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 54 |
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data. CNS Drugs 2017;31:273-88. [PMID: 28258365 DOI: 10.1007/s40263-017-0416-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 55 |
Smith CT, Dang LC, Buckholtz JW, Tetreault AM, Cowan RL, Kessler RM, Zald DH. The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum. Transl Psychiatry 2017;7:e1091. [PMID: 28398340 DOI: 10.1038/tp.2017.45] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 56 |
Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, Lee JS, Lee YS, Kwon JS. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [(18)F]DOPA PET Study. Neuropsychopharmacology 2017;42:941-50. [PMID: 27857125 DOI: 10.1038/npp.2016.258] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 57 |
Gomez-A A, Fiorenza AM, Boschen SL, Sugi AH, Beckman D, Ferreira ST, Lee K, Blaha CD, Da Cunha C. Diazepam Inhibits Electrically Evoked and Tonic Dopamine Release in the Nucleus Accumbens and Reverses the Effect of Amphetamine. ACS Chem Neurosci 2017;8:300-9. [PMID: 28038309 DOI: 10.1021/acschemneuro.6b00358] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 58 |
Li P, Snyder GL, Vanover KE. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem 2016;16:3385-403. [PMID: 27291902 DOI: 10.2174/1568026616666160608084834] [Cited by in Crossref: 134] [Cited by in F6Publishing: 138] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 59 |
Schill J, Olsson H. Do doctors agree on doses of antipsychotic medications? Ther Adv Psychopharmacol 2016;6:349-54. [PMID: 28008348 DOI: 10.1177/2045125316657796] [Reference Citation Analysis]
|
| 60 |
Maurel M, Belzeaux R, Adida M, Azorin J. Comment évaluer les effets indésirables au cours d’un essai clinique ? L'Encéphale 2016;42:S30-S32. [DOI: 10.1016/s0013-7006(17)30051-9] [Reference Citation Analysis]
|
| 61 |
Reinen JM, Van Snellenberg JX, Horga G, Abi-Dargham A, Daw ND, Shohamy D. Motivational Context Modulates Prediction Error Response in Schizophrenia. Schizophr Bull 2016;42:1467-75. [PMID: 27105903 DOI: 10.1093/schbul/sbw045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 62 |
De Rossi P, Chiapponi C, Spalletta G. Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems. Curr Neuropharmacol 2015;13:435-44. [PMID: 26412063 DOI: 10.2174/1570159x13666150507223542] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 63 |
Suzuki K, Harada A, Suzuki H, Miyamoto M, Kimura H. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms. Neuropsychopharmacology 2016;41:2252-62. [PMID: 26849714 DOI: 10.1038/npp.2016.20] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 64 |
Li YC, Yang SS, Gao WJ. Disruption of Akt signaling decreases dopamine sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex. Neuropharmacology 2016;108:403-14. [PMID: 27163190 DOI: 10.1016/j.neuropharm.2016.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 65 |
Kurita M, García-bea A, González-maeso J. Novel Targets for Drug Treatment in Psychiatry. The Medical Basis of Psychiatry 2016. [DOI: 10.1007/978-1-4939-2528-5_30] [Reference Citation Analysis]
|
| 66 |
Gründer G, Cumming P. The Dopamine Hypothesis of Schizophrenia. The Neurobiology of Schizophrenia 2016. [DOI: 10.1016/b978-0-12-801829-3.00015-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 67 |
Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treat 2016;12:1837-42. [PMID: 27524901 DOI: 10.2147/NDT.S97616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Landry P. A Neuroeconomic Theory of Attention- and Task-Switching with Implications for Autism and ADHD. SSRN Journal. [DOI: 10.2139/ssrn.2725953] [Reference Citation Analysis]
|
| 69 |
Neuroleptic drugs. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.01137-9] [Reference Citation Analysis]
|
| 70 |
Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MØ, Allerup P, Bak N, Rasmussen H, Frandsen E, Rostrup E, Glenthøj BY. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull 2015;41:1143-52. [PMID: 25698711 DOI: 10.1093/schbul/sbu220] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 71 |
Möller M, Swanepoel T, Harvey BH. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development. ACS Chem Neurosci 2015;6:987-1016. [PMID: 25794269 DOI: 10.1021/cn5003368] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 72 |
Jennings D. Imaging in medication-induced parkinsonism. Medication-Induced Movement Disorders 2015. [DOI: 10.1017/cbo9781107588738.017] [Reference Citation Analysis]
|
| 73 |
Cocchi E, Drago A, Serretti A. Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis. Mol Neurobiol 2016;53:2065-81. [PMID: 25902861 DOI: 10.1007/s12035-015-9174-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 74 |
Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 2015;29:97-115. [PMID: 25586400 DOI: 10.1177/0269881114563634] [Cited by in Crossref: 484] [Cited by in F6Publishing: 489] [Article Influence: 60.5] [Reference Citation Analysis]
|
| 75 |
Sethi SK, Varshney R, Rangaswamy S, Chadha N, Hazari PP, Kaul A, Chuttani K, Milton MD, Mishra AK. Design, synthesis and preliminary evaluation of a novel SPECT DTPA-bis-triazaspirodecanone conjugate for D 2 receptor imaging. RSC Adv 2014;4:50153-62. [DOI: 10.1039/c4ra07004f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 76 |
Bonoldi I, Howes OD. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis. CNS Drugs 2014;28:649-63. [PMID: 24919790 DOI: 10.1007/s40263-014-0177-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 77 |
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH. Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach. Pharm Res 2014;31:2605-17. [PMID: 24792824 DOI: 10.1007/s11095-014-1358-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 78 |
Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014;19:20-9. [PMID: 24166406 DOI: 10.1038/mp.2013.136] [Cited by in Crossref: 158] [Cited by in F6Publishing: 165] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 79 |
Herrmann M. Neuroleptikakombinationen: extrapyramidale Nebenwirkungen im Auge behalten. DNP 2013;14:24-24. [DOI: 10.1007/s15202-013-0491-1] [Reference Citation Analysis]
|
| 80 |
Lee C, Varnäs K, Farde L. IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES. Drug Delivery Applications of Noninvasive Imaging 2013. [DOI: 10.1002/9781118356845.ch20] [Reference Citation Analysis]
|
| 81 |
Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry 2013;74:122-9. [PMID: 23290498 DOI: 10.1016/j.biopsych.2012.11.018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 104] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 82 |
Varnäs K, Varrone A, Farde L. Modeling of PET data in CNS drug discovery and development. J Pharmacokinet Pharmacodyn 2013;40:267-79. [PMID: 23660778 DOI: 10.1007/s10928-013-9320-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 83 |
Venkatasubramanian G, Rao NP, Arasappa R, Kalmady SV, Gangadhar BN. A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics? Clin Psychopharmacol Neurosci 2013;11:24-7. [PMID: 23678351 DOI: 10.9758/cpn.2013.11.1.24] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 84 |
Geerts H, Spiros A, Roberts P, Twyman R, Alphs L, Grace AA. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS One 2012;7:e49732. [PMID: 23251349 DOI: 10.1371/journal.pone.0049732] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 85 |
Mihali A, Subramani S, Kaunitz G, Rayport S, Gaisler-Salomon I. Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother 2012;12:785-99. [PMID: 22853787 DOI: 10.1586/ern.12.60] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 86 |
Harada N, Ohba H, Kakiuchi T, Tsukada H. Application of feedback-controlled bolus plus infusion (FC-B/I) method for quantitative PET imaging of dopamine transporters with [(18)F]β-CFT-FE in conscious monkey brain. Synapse 2013;67:42-50. [PMID: 23042662 DOI: 10.1002/syn.21614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 87 |
The management of negative symptoms. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition 2012. [DOI: 10.3109/9781842145357-4] [Reference Citation Analysis]
|
| 88 |
Girault EM, Alkemade A, Foppen E, Ackermans MT, Fliers E, Kalsbeek A. Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One 2012;7:e43244. [PMID: 22905238 DOI: 10.1371/journal.pone.0043244] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 89 |
Copolov DL, Castle DJ. The management of negative symptoms. Pharmacological and Psychosocial Treatments in Schizophrenia 2012. [DOI: 10.3109/9781842145357.003] [Reference Citation Analysis]
|
| 90 |
Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011;3:102mr2. [PMID: 21957170 DOI: 10.1126/scitranslmed.3002804] [Cited by in Crossref: 118] [Cited by in F6Publishing: 131] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 91 |
Barth VN, Joshi EM, Silva MD. Target Engagement for PK/PD Modeling and Translational Imaging Biomarkers. ADME‐Enabling Technologies in Drug Design and Development 2012. [DOI: 10.1002/9781118180778.ch33] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 92 |
Integration of PBPK and Pharmacodynamics. Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations 2012. [DOI: 10.1002/9781118140291.ch13] [Reference Citation Analysis]
|
| 93 |
Barrie ES, Smith RM, Sanford JC, Sadee W. mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol 2012;81:620-30. [PMID: 22319206 DOI: 10.1124/mol.111.076604] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 94 |
Shao X. Synthesis of [11C]Raclopride. Radiochemical Syntheses 2012. [DOI: 10.1002/9781118140345.ch27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 95 |
Muly EC, Votaw JR, Ritchie J, Howell LL. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 2012;341:81-9. [PMID: 22214649 DOI: 10.1124/jpet.111.189076] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 96 |
El-Khalili N. Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. Neuropsychiatr Dis Treat 2012;8:523-36. [PMID: 23152684 DOI: 10.2147/NDT.S14369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 97 |
Trincavelli ML, Daniele S, Ciapparelli A, Dell’osso MC, Massimetti G, Marazziti D, Dell’osso L, Martini C. Changes in A<sub>2A</sub> adenosine receptor parameters in patients affected by bipolar disorders: Correlation with antipsychotic dosage and severity of illness. OJPsych 2012;02:1-8. [DOI: 10.4236/ojpsych.2012.21001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 98 |
Veselinović T, Schorn H, Vernaleken I, Schiffl K, Hiemke C, Zernig G, Gur R, Gründer G. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology (Berl) 2011;218:733-48. [PMID: 21643673 DOI: 10.1007/s00213-011-2368-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 99 |
Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011;25:829-45. [PMID: 21936586 DOI: 10.2165/11591690-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 34] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 100 |
Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. Curr Neuropharmacol 2009;7:302-14. [PMID: 20514210 DOI: 10.2174/157015909790031229] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 101 |
Sekine M, Maeda J, Shimada H, Nogami T, Arakawa R, Takano H, Higuchi M, Ito H, Okubo Y, Suhara T. Central nervous system drug evaluation using positron emission tomography. Clin Psychopharmacol Neurosci 2011;9:9-16. [PMID: 23431048 DOI: 10.9758/cpn.2011.9.1.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 102 |
Waddington JL, O'tuathaigh CMP, Remington GJ. Pharmacology and Neuroscience of Antipsychotic Drugs. Schizophrenia 2011. [DOI: 10.1002/9781444327298.ch23] [Reference Citation Analysis]
|
| 103 |
Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull 2011;37:108-17. [PMID: 19525353 DOI: 10.1093/schbul/sbp010] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 104 |
de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J 2011;13:121-30. [PMID: 21184291 DOI: 10.1208/s12248-010-9247-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 105 |
Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17:97-103. [PMID: 21143431 DOI: 10.1111/j.1755-5949.2010.00222.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 141] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 106 |
Vernaleken I, Gruender G, Cumming P. Progress in Psychopharmacotherapy though Molecular Imaging. Systems Biology in Psychiatric Research 2010. [DOI: 10.1002/9783527630271.ch9] [Reference Citation Analysis]
|
| 107 |
McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 2010;35:1826-35. [PMID: 20410873 DOI: 10.1038/npp.2010.50] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 108 |
Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 2008;6:117-24. [PMID: 19305792 DOI: 10.2174/157015908784533860] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 109 |
Abi-dargham A, Laruelle M. In Vivo Imaging of Dopamine Receptors. The Dopamine Receptors 2010. [DOI: 10.1007/978-1-60327-333-6_15] [Reference Citation Analysis]
|
| 110 |
Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009;120:416-28. [PMID: 19573049 DOI: 10.1111/j.1600-0447.2009.01429.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 111 |
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009;15:2550-9. [PMID: 19689327 DOI: 10.2174/138161209788957528] [Cited by in Crossref: 166] [Cited by in F6Publishing: 174] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 112 |
Roth BL, Rogan SC. 10.2 Neuropharmacological Profiles of Antipsychotic Drugs. Dopamine Handbook 2009. [DOI: 10.1093/acprof:oso/9780195373035.003.0037] [Reference Citation Analysis]
|
| 113 |
Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009;35:789-97. [PMID: 18303092 DOI: 10.1093/schbul/sbn009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 114 |
Sim K, Su HC, Fujii S, Yang SY, Chong MY, Ungvari G, Si T, He YL, Chung EK, Chan YH, Shinfuku N, Kua EH, Tan CH, Sartorius N. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009;67:110-7. [PMID: 19133060 DOI: 10.1111/j.1365-2125.2008.03304.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 115 |
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009;35:549-62. [PMID: 19325164 DOI: 10.1093/schbul/sbp006] [Cited by in Crossref: 1683] [Cited by in F6Publishing: 1771] [Article Influence: 120.2] [Reference Citation Analysis]
|
| 116 |
Liu-Seifert H, Kinon BJ, Tennant CJ, Sniadecki J, Volavka J. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009;5:47-54. [PMID: 19557099 DOI: 10.2147/ndt.s4766] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 117 |
NEUROLEPTIC DRUGS. Meyler's Side Effects of Psychiatric Drugs 2009. [DOI: 10.1016/b978-0-444-53266-4.50005-7] [Reference Citation Analysis]
|
| 118 |
Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008;197:229-35. [PMID: 18058087 DOI: 10.1007/s00213-007-1029-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 119 |
Management of Negative Symptoms. Pharmacological and Psychosocial Treatments in Schizophrenia 2008. [DOI: 10.3109/9780203091579-4] [Reference Citation Analysis]
|
| 120 |
Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 2007;9:329-36. [PMID: 17880866 DOI: 10.1007/s11920-007-0041-7] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 121 |
Sharif Z, Miyamoto S, Lieberman JA. Pharmacotherapy of Schizophrenia. Handbook of Contemporary Neuropharmacology 2007. [DOI: 10.1002/9780470101001.hcn033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 122 |
Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007;3:13-39. [PMID: 19300536 DOI: 10.2147/nedt.2007.3.1.13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 123 |
Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006;186:561-71. [PMID: 16758241 DOI: 10.1007/s00213-006-0368-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 124 |
Nesvåg R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006;114:21-6. [PMID: 16774657 DOI: 10.1111/j.1600-0447.2006.00840.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 125 |
Tashiro M, Mochizuki H, Sakurada Y, Ishii K, Oda K, Kimura Y, Sasaki T, Ishiwata K, Yanai K. Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 2006;61:16-26. [PMID: 16390347 DOI: 10.1111/j.1365-2125.2005.02514.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 126 |
Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. NeuroRx 2006;3:10-21. [PMID: 16490410 DOI: 10.1016/j.nurx.2005.12.003] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 127 |
Neuroleptic drugs. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions 2006. [DOI: 10.1016/b0-44-451005-2/00134-0] [Reference Citation Analysis]
|
| 128 |
Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour - review of data from preclinical research. Acta Psychiatr Scand 2005;111:14-21. [DOI: 10.1111/j.1600-0447.2005.00540.x] [Cited by in Crossref: 156] [Cited by in F6Publishing: 170] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 129 |
Abi-dargham A, Laruelle M. Mecanismos de acción de los medicamentos antipsicóticos de segunda generación en la esquizofrenia: conocimientos obtenidos a partir de los estudios de imágenes cerebrales. Eur psychiatr (Ed esp ) 2005;12:231-244. [DOI: 10.1017/s1134066500003520] [Reference Citation Analysis]
|
| 130 |
Frankle WG, Slifstein M, Talbot PS, Laruelle M. Neuroreceptor Imaging in Psychiatry: Theory and Applications. International Review of Neurobiology 2005. [DOI: 10.1016/s0074-7742(05)67011-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 131 |
Hurd YL, Hall H. Chapter IX Human forebrain dopamine systems: Characterization of the normal brain and in relation to psychiatric disorders. Handbook of Chemical Neuroanatomy 2005. [DOI: 10.1016/s0924-8196(05)80013-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 132 |
Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004;175:367-73. [PMID: 14997280 DOI: 10.1007/s00213-004-1826-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 133 |
Apiquian R, Fresán A, de la Fuente-Sandoval C, Ulloa RE, Nicolini H. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry 2004;4:12. [PMID: 15109398 DOI: 10.1186/1471-244X-4-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 134 |
Seeman P. Atypical Antipsychotics: Mechanism of Action. FOC 2004;2:48-58. [DOI: 10.1176/foc.2.1.48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 135 |
Stone J, Pilowsky LS. Schizophrenia and Psychotic Disorder. Nuclear Medicine in Psychiatry 2004. [DOI: 10.1007/978-3-642-18773-5_18] [Reference Citation Analysis]
|
| 136 |
Bigliani V, Pilowsky LS, Busatto G. Neuroreceptor Imaging Studies and the Mechanism of Action of Antipsychotic Drugs. Nuclear Medicine in Psychiatry 2004. [DOI: 10.1007/978-3-642-18773-5_8] [Reference Citation Analysis]
|
| 137 |
Pilowsky LS. What can molecular imaging tell us about schizophrenia? Search for the Causes of Schizophrenia 2004. [DOI: 10.1007/978-3-7985-1953-4_29] [Reference Citation Analysis]
|
| 138 |
Meltzer H. Multiple neurotransmitters involved in antipsychotic drug action. Dopamine in the Pathophysiology and Treatment of Schizophrenia 2003. [DOI: 10.3109/9780203427347-10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 139 |
Modulation of dopamine D2 receptors as a basis of antipsychotic effect. Dopamine in the Pathophysiology and Treatment of Schizophrenia 2003. [DOI: 10.3109/9780203427347-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 140 |
Gemperle AY, McAllister KH, Olpe HR. Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology (Berl) 2003;169:354-64. [PMID: 12827343 DOI: 10.1007/s00213-003-1459-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 141 |
Gulyás B, Halldin C, Sandell J, Karlsson P, Sóvágó J, Kárpáti E, Kiss B, Vas A, Cselényi Z, Farde L. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol Scand 2002;106:325-32. [PMID: 12460136 DOI: 10.1034/j.1600-0404.2002.01302.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 142 |
Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-30. [PMID: 12366465 DOI: 10.1034/j.1600-0447.2002.01331.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 166] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 143 |
Möller H. Drug Treatment of Schizophrenia: State of the Art and the Potential of the Atypical Neuroleptics. New Family Interventions and Associated Research in Psychiatric Disorders 2002. [DOI: 10.1007/978-3-7091-6148-7_14] [Reference Citation Analysis]
|
| 144 |
Weiner I, Joel D. Dopamine in Schizophrenia Dysfunctional Information Processing in Basal Ganglia — Thalamocortical Split Circuits. Dopamine in the CNS II 2002. [DOI: 10.1007/978-3-662-06765-9_13] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 145 |
Schmidt ME. The Future of Imaging in Drug Discovery. Journal of Pharmacy Practice 2001;14:427-434. [DOI: 10.1177/089719001129040766] [Reference Citation Analysis]
|
| 146 |
Verhoeff NPLG, Kapur S. The Role of Neuroimaging in Development of and Treatment With Antipsychotics. Journal of Pharmacy Practice 2001;14:332-340. [DOI: 10.1106/ryyj-eemb-9ka4-d5dh] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 147 |
Kapur S. Neuroimaging and Drug Development: An Algorithm for Decision Making. The Journal of Clinical Pharma 2001;41. [DOI: 10.1177/0091270001417010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 148 |
Kalkman HO. The Interaction of Atypical Neuroleptics with Monoamine Receptor Subtypes. Leponex 2001. [DOI: 10.1007/978-3-642-59454-0_6] [Reference Citation Analysis]
|
| 149 |
Kapur S. Receptor Occupancy by Antipsychotics — Concepts and Findings. Neurotransmitter Receptors in Actions of Antipsychotic Medications 2000. [DOI: 10.1201/9781420041774.ch11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 150 |
Saleem A, Aboagye EO, Price PM. In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev 2000;41:21-39. [PMID: 10699303 DOI: 10.1016/s0169-409x(99)00054-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 151 |
Wong AH, Sanyal S, Knapp MG, Van Tol HH. Potential therapeutic targets for schizophrenia. Emerging Therapeutic Targets 1999;3:571-586. [DOI: 10.1517/14728222.3.4.571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 152 |
Bryant CA, Jackson SH. Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs Aging 1998;13:211-22. [PMID: 9789725 DOI: 10.2165/00002512-199813030-00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 153 |
Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A 1998;95:7731-6. [PMID: 9636219 DOI: 10.1073/pnas.95.13.7731] [Cited by in Crossref: 197] [Cited by in F6Publishing: 210] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 154 |
Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998;34:227-63. [PMID: 9533984 DOI: 10.2165/00003088-199834030-00005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 155 |
Lingford-hughes A. Psychiatric disorders. Clinical Nuclear Medicine 1998. [DOI: 10.1007/978-1-4899-3356-0_26] [Reference Citation Analysis]
|
| 156 |
Lindström LH, Wieselgren IM. Schizophrenia and antipsychotic somatic treatment. Int J Technol Assess Health Care 1996;12:573-84. [PMID: 9136468 DOI: 10.1017/s0266462300010898] [Reference Citation Analysis]
|
| 157 |
Bossé R, DiPaolo T. The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause. Cell Mol Neurobiol 1996;16:199-212. [PMID: 8743969 DOI: 10.1007/BF02088176] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 158 |
Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996;124:148-53. [PMID: 8935810 DOI: 10.1007/BF02245615] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 159 |
Martinot JL, Paillère-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Mazière B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996;124:154-8. [PMID: 8935811 DOI: 10.1007/BF02245616] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 160 |
Bardgett ME, Csernansky JG. Antipsychotic Drug Action After Lesions to the Hippocampus or Frontal Cortex. Antipsychotics 1996. [DOI: 10.1007/978-3-642-61007-3_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 161 |
Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, Ito K, Itoh M. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649-55. [PMID: 8564232 DOI: 10.1111/j.1476-5381.1995.tb16386.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 162 |
Halldin C, Suhara T, Farde L, Sedvall G. Preparation and Examination of Labelled Stereoisomers in Vivo by Pet. Chemists’ Views of Imaging Centers 1995. [DOI: 10.1007/978-1-4757-9670-4_53] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 163 |
Nyberg S, Nordström A, Halldin C, Farde L. Is the 5-HT2-Receptor a Target for Antipsychotic Drug Action? PET Studies on Dopamine (D2 and Serotonin (5-HT2) Receptor Occupancy in Patients and Healthy Subjects. PET for Drug Development and Evaluation 1995. [DOI: 10.1007/978-94-011-0429-6_8] [Reference Citation Analysis]
|
| 164 |
Farde L. PET-Studien zur Dopaminrezeptorbindung bei neuroleptisch behandelten Patienten. Schizophrenie 1995. [DOI: 10.1007/978-3-642-79738-5_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 165 |
Casey DE. Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl 1994;380:14-20. [PMID: 7914042 DOI: 10.1111/j.1600-0447.1994.tb05826.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 166 |
Capellà D, Figueras A. Antipsychotic drugs. Side Effects of Drugs Annual 1994. [DOI: 10.1016/s0378-6080(05)80250-8] [Reference Citation Analysis]
|
